^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Anal Carcinoma

No biomarker
Anal Carcinoma
MIXE
Sensitive
:
A2
No biomarker
Anal Carcinoma
TPF
Sensitive
:
A2
No biomarker
Anal Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Anal Carcinoma
nivolumab
Sensitive
:
A2
No biomarker
Anal Carcinoma
FOLFOX
Sensitive
:
A2
No biomarker
Anal Carcinoma
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Anal Carcinoma
FOLFCIS
Sensitive
:
A2
No biomarker
Anal Carcinoma
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Anal Carcinoma
mFOLFOX6
Sensitive
:
A2
No biomarker
Anal Carcinoma
capecitabine
Sensitive
:
A2
No biomarker
Anal Carcinoma
5-fluorouracil
Sensitive
:
A2
No biomarker
Anal Carcinoma
DCF
Sensitive
:
A2
No biomarker
Anal Carcinoma
cisplatin + docetaxel
Sensitive
:
A2
No biomarker
Anal Carcinoma
cisplatin + carboplatin
Sensitive
:
A2
No biomarker
Anal Carcinoma
cisplatin + 5-fluorouracil + capecitabine
Sensitive
:
A2
PD-L1 expression
Anal Carcinoma
pembrolizumab
Sensitive
:
C1
PD-L1 overexpression + TMB-H
Anal Carcinoma
EGFR inhibitor + Immunotherapy
Sensitive
:
C3
CD163 expression
Anal Carcinoma
toripalimab
Sensitive
:
C3
CD4 expression
Anal Carcinoma
toripalimab
Sensitive
:
C3
PD-L1 expression
Anal Carcinoma
toripalimab
Sensitive
:
C3
PD-L1 amplification + PD-L2 amplification + TMB-H
Anal Carcinoma
pembrolizumab
Sensitive
:
C4